Quantum BioPharma Clears the Air: Addresses Platform Misinformation, Provides Update on Strategic Partnership
TORONTO, June 3, 2025 – In a move designed to clarify recent market developments, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) has issued a statement addressing recent confusion stemming from stock trading platforms and social media chatter. Despite some platforms incorrectly listing Quantum BioPharma under a different name, the company confirms that its corporate identity remains unchanged.
The company also addressed rumors circulating on social media, specifically regarding Unbuzzd Wellness Inc., the firm behind the scientifically-backed product designed to accelerate alcohol metabolism and reduce hangover symptoms. Quantum BioPharma wishes to clarify that there is no reverse takeover transaction (RTO) currently underway between the two entities.
Unbuzzd Wellness Inc. is preparing for a potential initial public offering (IPO). Recent steps include the engagement of leading audit firm MNP LLP to conduct audits of its financial statements in preparation for a potential IPO. This follows the company’s prior announcement that it had retained a New York investment bank to advise on a capital raise and explore an IPO, pending regulatory approvals.
From a commercial standpoint, Quantum BioPharma has a significant stake in the success of Unbuzzd Wellness Inc. The agreement between both companies stipulates that Quantum will receive a 7% royalty on Unbuzzd Wellness Inc.’s revenue until payments reach $250 million, after which the rate will be reduced to 3%. Furthermore, Unbuzzd Wellness Inc. has issued Quantum 200,000,000 post-split common shares as a license fee. A built-in anti-dilution warrant gives Quantum the ability to increase their holding in the company to 25% for a nominal fee within the next three years. A public offering would see Quantum BioPharma owning at least 25% of Unbuzzd Wellness Inc. Additionally, Quantum BioPharma loaned Unbuzzd Wellness Inc. $1,300,000 on a secured basis with a 3-year term at 10% per annum, payable annually.
Unbuzzd Wellness Inc. benefits from the experienced leadership of CEO John Duffy, a veteran of The Coca-Cola Company and Coca-Cola Enterprises, and strategic counsel from Gerry David, former CEO of Celsius Holdings, Inc.
In other financial news, the company is authorized debt settlement for two vendors totaling $20,930 with Class B Shares, expected to be completed around the first week of June 2025.
**About Quantum BioPharma Ltd.**
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company focused on developing innovative solutions for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is advancing its lead drug candidate, Lucid-MS, through its wholly- owned subsidiary, Lucid Psycheceuticals Inc. Lucid-MS is a patented new chemical entity designed to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical studies. Quantum BioPharma invented unbuzzd™ and spun its over-the-counter version out to Unbuzzd Wellness Inc., which retains ownership of 20.11% of the company as of March 31, 2025, while holding onto rights to develop similar products, including pharmaceutical and medical uses.
**About Unbuzzd Wellness Inc.**
Unbuzzd Wellness Inc., a fully reporting public issuer, is at the forefront of the wellness and recovery supplement market. The unbuzzd supplement, developed by a world-class team of pharmacology and medicine researchers, aids in alcohol metabolism, restores mental clarity and reduces hangover symptoms.
The product, which has recently shown positive results in a double-blind trial, accelerates alcohol metabolism, speeds the reduction of blood alcohol concentration and has been shown to ease symptoms of intoxication and hangovers. unbuzzd ready-to-mix powder sticks are available in 3-pack, 8-pack, and 18-pack formats.
**Forward-Looking Statements**
*Important note: This content includes forward-looking statements. Actual results could vary.*
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/1631.html
